Teva Pharm nudges up earnings forecast, names new CFO
JERUSALEM (Reuters) – Teva Pharmaceutical Industries (TEVA.TA) nudged up its full-year earnings guidance on Thursday, after reporting a drop in third-quarter profit that broadly met expectations. The world’s largest generic drugmaker earned 58 cents per diluted share excluding one-time items in the July-September period, down from 68 cents a year earlier. It cited higher tax expenses and lower operating profit, […]
Read more